Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells $44,920.00 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total value of $44,920.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jeffrey Dierks also recently made the following trade(s):

• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.01, for a total value of $388,864.07.
• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.47, for a total value of $869,943.12.

Harmony Biosciences Trading Up 3.6 %

Shares of HRMY stock traded up $1.41 on Tuesday, reaching $40.46. 844,300 shares of the stock were exchanged, compared to its average volume of 559,483. The stock has a market cap of $2.31 billion, a PE ratio of 19.18, a P/E/G ratio of 0.54 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock has a 50 day moving average price of $34.46 and a 200 day moving average price of $34.96.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. During the same quarter in the previous year, the company posted $0.63 earnings per share. The firm’s quarterly revenue was up 16.0% on a year-over-year basis. Equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Harmony Biosciences

Several hedge funds have recently added to or reduced their stakes in HRMY. GAMMA Investing LLC increased its holdings in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares in the last quarter. Mendota Financial Group LLC increased its holdings in shares of Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after acquiring an additional 965 shares in the last quarter. CWM LLC increased its holdings in shares of Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after acquiring an additional 775 shares in the last quarter. Quarry LP bought a new stake in shares of Harmony Biosciences in the second quarter worth about $62,000. Finally, Quantbot Technologies LP bought a new stake in shares of Harmony Biosciences in the third quarter worth about $74,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on HRMY shares. Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Monday, January 13th. Mizuho lifted their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Harmony Biosciences in a research report on Thursday, January 16th. Finally, Raymond James reiterated an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.